News

Last Chance to Own Luxury Townhomes at 717 Lyon Community

Last Chance to Own Luxury Townhomes at 717 Lyon Community

Final Opportunity to Own at 717 Lyon Community

Toll Brothers, Inc. (NYSE:TOL) recently announced an exciting opportunity for home buyers looking for luxury living in the heart of Southern California. The 717 Lyon community is a standout for its modern design and prime location, and only a few residences remain available for immediate purchase. This exclusive development includes a beautifully furnished model home, reflecting the quality and elegance typical of Toll Brothers’ offerings.

Community Features and Home Designs

The 717 Lyon community promises a harmonious blend of luxury and practicality within a secure gated setting. Each of the three-story townhomes boasts attached two-car garages and contemporary open-concept layouts. Prices start from the upper $700,000s. This makes it an appealing choice for those desiring spacious living in a dynamic urban atmosphere.

Exceptional Living Spaces

One of the highlights is the Lyon 3 model home, available for $999,000. This stunning home is equipped with top-tier finishes and is fully furnished, offering an effortless move-in experience for prospective homeowners. The design emphasizes both comfort and sophistication, catering to a modern lifestyle.

Prime Location Benefits

The 717 Lyon community provides easy access to a wealth of local amenities and attractions. Situated just minutes away from the Downtown Santa Ana Historic District, residents are close to an array of shops, restaurants, and outdoor recreational spaces. Moreover, the proximity to major highways and John Wayne Airport ensures convenient travel and connectivity.

A Centralized Community

Brad Hare, Division President of Toll Brothers in Southern California, highlights, "This is the last chance for home shoppers to call 717 Lyon home. With its central location and premium finishes, this community offers unmatched convenience and luxury living." This statement underscores the unique selling points of a community that balances lifestyle and accessibility.

Explore Toll Brothers and Its Legacy

Toll Brothers, Inc. is renowned as the nation's leading builder of luxury homes. Established over 58 years ago and publicly traded since 1986, the company continues to be a pioneer in the residential construction market. With operations spanning over 60 markets across 24 states and the District of Columbia, Toll Brothers is committed to meeting the diverse needs of first-time buyers as well as luxury homeowners.

Builder Recognition

Throughout the years, Toll Brothers has received numerous accolades, including being listed as one of Fortune magazine's World's Most Admired Companies for over ten years. Most recently, CEO Douglas C. Yearley, Jr. was recognized among the top CEOs by Barron's magazine, underlining the company's dedication to excellence in homebuilding.

Contact Toll Brothers for More Information

The Sales Center for Toll Brothers is located at 717 South Lyon Street and is open daily for potential buyers. Interested individuals can reach out by calling 866-232-1631 or visiting their website for more details.

Frequently Asked Questions

What types of homes are available at 717 Lyon?

The 717 Lyon community offers modern townhome-style condominiums designed with spacious, open-concept layouts.

What is the pricing range for homes at this community?

Homes at 717 Lyon start from the upper $700,000s, making it a competitive option in the Orange County market.

Where is the 717 Lyon community located?

This community is located near the Downtown Santa Ana Historic District, providing easy access to shops, restaurants, and entertainment.

How can I visit the Toll Brothers Sales Center?

The Sales Center is open daily and is located at 717 South Lyon Street. Interested buyers can visit or call for more information.

What can I expect from the model homes?

The model homes are designed with professional finishes and are fully furnished, providing a turnkey living experience.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es